Why do platelets not return to normal after treatment with venetoclax?

Venetoclax, as a targeted therapy drug for B cell lymphoma-2 (BCL-2) protein, is used in chronic lymphocytic lymphoma It has shown remarkable results in the treatment of leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). However, after using venetoclax, some patients' platelet counts do not return to normal as expected, or even remain low. The reasons behind this phenomenon deserve further exploration.

Venetoclax may cause myelosuppression during the initial stages of treatment because rapid apoptosis of tumor cells takes up space in the bone marrow and interferes with the normal process of platelet production. Long-term medication is more likely to aggravate the damage to bone marrow function, making the problem of insufficient platelet production more serious.

In addition, the patient's underlying disease status is also an important factor affecting platelet recovery. Many leukemia patients have underlying conditions such as myelodysplasia before treatment, which themselves can lead to insufficient platelet production. At the same time, whether the patient has received other treatments, such as chemotherapy or radiation therapy, will also have an impact on platelet levels.

In certain circumstances, venetoclax may also trigger changes in the immune system, leading to an abnormal immune response, which in turn attacks one's own platelets, further reducing the platelet count. This condition is called immune thrombocytopenia and requires targeted therapeutic intervention.

In addition, interactions between venetoclax and other medications may also affect platelet levels. Thrombocytopenia may be exacerbated if patients are concurrently taking other drugs with myelosuppressive effects. Therefore, patients should maintain close communication with their doctor while taking venetoclax to avoid potential drug interactions.

For cases where platelets have not returned to normal, patients should have regular blood tests and keep in close contact with their doctors. Doctors will evaluate the condition based on the test results and may adjust the treatment plan or add symptomatic treatment measures, such as blood transfusions or other drugs to stimulate platelet production.